Master Medicine Protocol for the Administration of MMRVAXPRO (MMR ‐ Measles, Mumps and Rubella) live vaccine for MMR catch‐up vaccination programme and in the event of an outbreak

HSE National Immunisation Office

dc.contributor.author	HSE National Immunisation Office
dc.date.accessioned	2024-11-07T12:27:16Z
dc.date.available	2024-11-07T12:27:16Z
dc.date.issued	2024-06
dc.identifier.uri	http://hdl.handle.net/10147/643308
dc.description	1. All children at 12 months of age should receive a MMRVAXPRO vaccine under primary childhood immunisation programme, with a second dose at 4‐5 years of age (usually given in junior infants) 2. Children and adults presenting late for vaccine or without a written record or reliable verbal history of previously receiving MMR. 3. Measles outbreak – during an outbreak MMRVAXPRO vaccine may be given as young as 6 months of age. A dose given < 12 months of age does not replace the dose recommended at 12 months of age.	en_US
dc.language.iso	en	en_US
dc.publisher	Health Service Executive	en_US
dc.relation.ispartofseries	NIO March 2024	en_US
dc.rights	Attribution 4.0 International	*
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/	*
dc.subject	public health	en_US
dc.subject	INFECTIOUS DISEASES	en_US
dc.subject	MEASLES MUMPS RUBELLA VACCINE (MMR)	en_US
dc.title	Master Medicine Protocol for the Administration of MMRVAXPRO (MMR ‐ Measles, Mumps and Rubella) live vaccine for MMR catch‐up vaccination programme and in the event of an outbreak	en_US
dc.type	Protocol	en_US
dc.contributor.affiliation	Health Protection Surveillance Centre (HPSC)	en
refterms.dateFOA	2024-11-07T12:27:18Z